Addyi (Flibanserin) in Children Under 12: What Caregivers Must Know

Why Flibanserin Has No Use in Children Under 12

Flibanserin is not a medication for children. Full stop. The drug was developed specifically to treat hypoactive sexual desire disorder (HSDD) in premenopausal adult women, a condition defined by a persistent lack of sexual desire that causes personal distress. HSDD, by definition, does not apply to prepubertal children.

The FDA approved flibanserin in August 2015 with a narrowly drawn indication: one 100 mg tablet taken by mouth at bedtime, for premenopausal women only. The agency has never reviewed, evaluated, or granted any pediatric indication for this drug. No clinical trials have enrolled children under 12. No pharmacokinetic data exists for this age group.

The Pharmacology Explains the Risk

Flibanserin works as a serotonin 1A receptor agonist and serotonin 2A receptor antagonist, with additional activity at dopamine D4 receptors. In adult women, this combination modestly shifts the neurochemical balance in brain circuits governing desire. In a child whose central nervous system is still developing, the same receptor activity carries unpredictable consequences for sedation, blood pressure, and neurological function that have never been characterized in any study.

The drug's most serious risks in adults, including severe hypotension and loss of consciousness, are compounded by CNS immaturity in young children. A child's lower body weight means the same 100 mg dose delivers far higher plasma concentrations per kilogram than in an adult woman.

No Off-Label Rationale Exists

Some medications are used off-label in children when biological plausibility exists, adult evidence is strong, and the risk-benefit ratio is defensible. None of those conditions apply to flibanserin in anyone under 12. There is no disease state in this age group that flibanserin is hypothetically suited to treat. Any off-label use would be scientifically unsupported and ethically unjustifiable.

What Happens If a Child Under 12 Accidentally Ingests Flibanserin

Accidental ingestion is the only realistic scenario in which a child under 12 would encounter this drug, typically because a tablet was left accessible in a household where an adult woman has a prescription.

Call Poison Control immediately: 1-800-222-1222.

Do not wait for symptoms. Do not induce vomiting unless directed by Poison Control or emergency medical staff. Go to the nearest emergency department if your child is unconscious, breathing abnormally, or cannot be roused.

Expected Toxicity Profile Based on Adult Pharmacology

Because no pediatric overdose data exists, clinicians must extrapolate from adult adverse event data and general CNS depressant pharmacology. Based on the FDA prescribing information and the drug's mechanism, a child who ingests flibanserin may experience:

• Profound sedation and somnolence. In adult trials, somnolence occurred in approximately 11% of patients at therapeutic doses. In a child, sedation at a full adult dose could be severe.
• Hypotension and syncope. Blood-pressure drops are documented even without alcohol co-ingestion in adults. A child's lower baseline blood pressure magnifies this risk.
• Nausea and vomiting. Common at therapeutic adult doses; likely at accidental pediatric doses.
• CNS depression. The combination of serotonergic, dopaminergic, and sedative activity could produce prolonged altered consciousness in a child.

No antidote exists. Management is supportive, with monitoring of blood pressure, heart rate, respiratory status, and level of consciousness.

The Alcohol Interaction Is a Separate Danger in the Home

Flibanserin carries an FDA black box warning for the combination of flibanserin and alcohol, which can cause severe hypotension and syncope. While a child under 12 is unlikely to co-ingest alcohol, caregivers should know that even mouthwash, cooking extracts, or certain liquid medications containing ethanol could theoretically interact if ingested alongside a flibanserin tablet. This is an edge-case scenario, but Poison Control should be informed of anything else the child may have consumed.

Safe Storage: A Caregiver's Practical Checklist

If you are a premenopausal adult woman prescribed flibanserin and you live with or care for children under 12, storage discipline is non-negotiable. The following framework is adapted from general child medication safety principles published by the CDC and applied specifically to flibanserin's risk profile.

The WomanRx Flibanserin Home Safety Framework for Households with Children

Before you fill the prescription:

• Identify a dedicated locked storage location before the medication enters your home. A lockable medicine cabinet or a small combination lockbox works. A high shelf does not.
• Brief all adults in the household on the drug name, what it looks like (a pink, circular 100 mg tablet), and what to do if a child is found with it.

Daily use:

• Take your tablet at bedtime, immediately before sleep, as directed. This is both the clinically recommended timing and the safest window from a household exposure standpoint, because you are not leaving the tablet unattended on a counter.
• Never pre-sort flibanserin into unlocked weekly pill organizers that children could access.
• If you skip a dose, return the tablet to the locked container immediately. Do not leave it on a nightstand.

Disposal:

• Do not flush or bin unused tablets where children could find them. Use an FDA-approved drug take-back location or follow your pharmacy's disposal instructions.
• If no take-back is available, mix the tablet with an undesirable substance such as used coffee grounds, seal it in a bag, and place it in household trash in a location children cannot reach.

Travel:

• Carry flibanserin in a locked travel case. Hotel rooms, handbags, and unlocked luggage are not safe storage in households or environments with children.

Sex-Specific Physiology: Why This Drug Was Designed for Adult Women, Not Children

Understanding why flibanserin has no pediatric application requires a brief look at the neurobiology of female sexual desire across the life span.

The Hormonal Architecture of Desire

Sexual desire in women is shaped by the interplay of estrogen, progesterone, testosterone, and central neurotransmitters including serotonin and dopamine. Before puberty, a girl's hypothalamic-pituitary-gonadal axis is quiescent. Estrogen and androgen levels are low. The neurochemical circuits that flibanserin targets are present but not yet organized around reproductive function.

Flibanserin was tested in women with fully mature hormonal axes. The VIOLET trial, one of three key phase 3 trials submitted for FDA approval, enrolled only premenopausal women aged 22 to 50. The BEGONIA trial similarly enrolled premenopausal women. Neither trial included adolescents, and the target population was explicitly defined by hormonal maturity, not just age.

What Changes Across the Female Life Span

• Before puberty (under 12): No hormonal substrate for HSDD exists. No indication for flibanserin exists.
• Adolescence (12 to 17): Hormonal development is underway, but flibanserin is still not approved for this group, and no data supports its use.
• Reproductive years (18 to approximately 45): The FDA-approved target population. Clinical trials were conducted here.
• Perimenopause: Flibanserin is not approved for perimenopausal or postmenopausal women. The Menopause Society notes that low desire in menopause has different contributing factors, including genitourinary syndrome of menopause, and different evidence-based treatments.
• Postmenopause: Not an approved indication. Bremelanotide (Vyleesi) is also approved only for premenopausal women.

This life-stage specificity is not arbitrary. It reflects the biology of the condition the drug treats.

Pregnancy, Lactation, and Contraception: Required Disclosures for Adult Women Prescribed Flibanserin

This section is directed at adult women who are prescribed or considering flibanserin, not at caregivers of young children. It is included here because any drug article on this site requires full pregnancy and lactation disclosure.

Pregnancy

Flibanserin is contraindicated in pregnancy. The FDA prescribing label states that animal reproductive studies showed adverse developmental effects at doses below the human clinical dose. Human pregnancy data is limited to case reports and does not support safety conclusions. If you become pregnant while taking flibanserin, stop the medication and contact your prescriber.

Because the drug is indicated for premenopausal women who are presumably sexually active, contraception is a practical consideration. Flibanserin does not interact with hormonal contraceptives in a clinically meaningful way based on current data, but women using combined oral contraceptives should know that the CYP3A4 inhibitory effect of some oral contraceptive formulations may increase flibanserin plasma concentrations modestly. Discuss your contraceptive method with your prescriber.

Lactation

No human lactation data exists for flibanserin. The drug's lipophilicity suggests some transfer into breast milk is possible, but the extent is unknown. The FDA label recommends that women not breastfeed while taking flibanserin. This is the most conservative guidance available given the absence of data. If you are postpartum and considering treatment for low desire, discuss timing and alternatives with your clinician before restarting any medication.

Contraception Requirements

Flibanserin is not classified as a teratogen requiring mandatory contraception in the same regulatory category as thalidomide or isotretinoin. However, given the lack of human pregnancy safety data and the demonstrated animal harm, your prescriber should discuss reliable contraception before initiating treatment if you are sexually active and could become pregnant.

Who Flibanserin Is For and Who It Is Not For: A Life-Stage Summary

Flibanserin works for a narrow, well-defined population. Knowing who is outside that population matters as much as knowing who is inside it.

Appropriate Candidates

• Premenopausal adult women aged 18 and older
• Women with a diagnosis of generalized acquired HSDD (low desire present in most situations, not tied to a specific partner or circumstance, and acquired after a period of normal desire)
• Women who have had an adequate trial of addressing relationship and contextual factors
• Women who do not drink alcohol, or who are willing to abstain completely (the black box warning is absolute for alcohol co-ingestion)
• Women who are not taking moderate or strong CYP3A4 inhibitors, including fluconazole, clarithromycin, and many antiretrovirals, which can raise flibanserin concentrations to dangerous levels

Not Appropriate Candidates

• Children under 12. No indication, no data, no clinical rationale.
• Adolescents under 18. Not approved; no trial data.
• Perimenopausal or postmenopausal women. Not an approved indication; different pathophysiology applies.
• Pregnant women. Contraindicated.
• Breastfeeding women. Avoid due to lack of safety data.
• Women with hepatic impairment. Contraindicated by FDA label due to dramatically elevated drug exposure.
• Women who drink alcohol and are unwilling or unable to abstain completely.

The Evidence Gap: What We Don't Know About Flibanserin in Women

Women have historically been under-represented in clinical pharmacology trials, and flibanserin is an unusual case where the drug was developed exclusively for women but still left significant evidence gaps.

The three key trials, DAISY, VIOLET, and BEGONIA, enrolled a combined total of approximately 2,400 premenopausal women and showed statistically significant but modest improvements in satisfying sexual events: roughly 0.5 to 1.0 additional satisfying sexual events per month compared to placebo. The FDA's own advisory committee voted 18 to 6 in favor of approval only after two prior rejections, reflecting genuine uncertainty about the benefit-risk profile.

What remains uncharacterized in women:

• Long-term neurological effects beyond 24 weeks of treatment
• Effects in women over 50 who are perimenopausal but not yet postmenopausal
• Pharmacokinetics across the menstrual cycle (estrogen and progesterone fluctuations may affect CYP3A4 activity and therefore flibanserin clearance, but this has not been formally studied)
• Effects in women with PCOS, where androgen excess and insulin resistance may alter the neurochemical substrate of desire differently than in women without PCOS
• Real-world alcohol exposure outcomes beyond the controlled crossover study that generated the black box warning

The ACOG has noted that shared decision-making and thorough discussion of the modest benefit-risk data are essential before prescribing flibanserin. As a woman considering this medication, you deserve a full and honest conversation about what the drug does and does not do.

What Clinicians and Prescribers Need to Document for Households with Pediatric Members

When a prescriber writes a flibanserin prescription for a woman who lives with children under 12, the clinical encounter should include specific guidance beyond the standard REMS-era counseling points. The FDA's REMS (Risk Evaluation and Mitigation Strategy) for flibanserin was removed in 2019, which means the formal pharmacist-level counseling requirements no longer exist. The responsibility has shifted back to the prescriber and the patient.

Prescribers should:

• Document that the patient was counseled on locked storage specifically because of pediatric household members
• Provide or direct the patient to Poison Control contact information: 1-800-222-1222
• Confirm the patient understands that a child ingesting one tablet constitutes a medical emergency
• Note the alcohol interaction warning with particular care if older children in the household might also access alcohol-containing products

Patients should not need to figure out these safety steps on their own. If your prescriber did not cover home storage safety at the time of prescribing, raise it directly and ask for written guidance.

A Note on HSDD Treatment in the Context of Female Sexual Health Across Life Stages

HSDD is common. Approximately 10% of premenopausal women meet diagnostic criteria for HSDD with associated distress. The condition is under-recognized and under-treated, partly because clinical training in female sexual medicine remains inconsistent and partly because women have been told for decades that low desire is simply part of being a woman.

It is not. Low desire that causes you distress deserves clinical attention.

Flibanserin is one tool, with modest efficacy and significant interaction risks. Other evidence-based approaches for premenopausal women include psychotherapy (particularly cognitive behavioral therapy and mindfulness-based interventions), off-label testosterone therapy, treatment of underlying conditions such as depression, thyroid dysfunction, or PCOS, and addressing relationship factors with a qualified sex therapist.

For perimenopausal and postmenopausal women, the conversation shifts. Genitourinary syndrome of menopause (GSM) is a major contributor to low desire in this group, and local vaginal estrogen, ospemifene, or systemic hormone therapy may be more appropriate first steps than any centrally acting drug. The Menopause Society's 2022 position statement on hormone therapy addresses this in detail.